AstraZeneca PLC

AZN

Company Profile

  • Business description

    A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.

  • Contact

    1 Francis Crick Avenue
    Cambridge Biomedical Campus
    CambridgeCB2 0AA
    GBR

    T: +44 2037495000

    E: [email protected]

    https://www.astrazeneca.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2025

    Employees

    94,300

AstraZeneca PLC News & Analysis

markets

What are emerging and frontier markets?

Power blocs, frontier stocks and investor shocks explained as the world becomes more complex 
stocks

Magnificent Seven vs. the ‘Granolas’: How does Europe’s version stack up?

‘Granolas’ stocks are profitable, diversified, cheap—and posting big returns.
stocks

Best international companies to own: 2023 Edition

These companies from various corners of the globe are well positioned for the future.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,137.8014.900.16%
CAC 407,872.0241.910.54%
DAX 4023,611.3384.280.36%
Dow JONES (US)46,292.7888.76-0.19%
FTSE 1009,223.323.36-0.04%
HKSE26,159.12185.02-0.70%
NASDAQ22,573.47215.50-0.95%
Nikkei 22545,493.66447.850.99%
NZX 50 Index13,136.545.00-0.04%
S&P 5006,656.9236.83-0.55%
S&P/ASX 2008,845.9014.300.16%
SSE Composite Index3,821.836.74-0.18%

Market Movers